• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Rotman Avner claimed ownership of 205,580 units of Ordinary Shares (Amendment)

    1/23/23 8:00:02 AM ET
    $BVXV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BVXV alert in real time by email
    SEC FORM 3/A SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Rotman Avner

    (Last) (First) (Middle)
    JERUSALEM BIOPARK,
    2ND FLOOR HADASSAH EIN KEREM CAMPUS

    (Street)
    JERUSALEM L3 9112001

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    01/01/2023
    3. Issuer Name and Ticker or Trading Symbol
    BiondVax Pharmaceuticals Ltd. [ BVXV ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    01/03/2023
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Ordinary Shares(1) 138,780 D
    Ordinary Shares(1) 66,800 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options (right to buy) (2) 11/19/2029 Ordinary Shares(1) 720,000 0.182 D
    Stock Options (right to buy) (3) 04/06/2031 Ordinary Shares(1) 1,000,000 0.174 D
    Restricted Share Units (4) 04/06/2031(4) Ordinary Shares(1) 133,200 (5) D
    Explanation of Responses:
    1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents four hundred Ordinary Shares.
    2. Stock options were granted on March 24, 2020 and are fully vested.
    3. Stock options were granted on April 6, 2021, and vest on a monthly basis during a period of three years.
    4. Restricted share units were granted on April 6, 2021, and vest on a monthly basis during a period of three years.
    5. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share.
    /s/ Avner Rotman 01/23/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BVXV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BVXV

    DatePrice TargetRatingAnalyst
    1/26/2022$7.00Buy
    Aegis Capital
    More analyst ratings

    $BVXV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

      JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. ("Scinai"). In the past two years, the Company has substantially revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices. The new corporate name, which was approved by the Israeli authorities on August 31, is the Company's latest step to better reflect its fresh start and new direction. Scinai and its new symbol, "SCNI", will debut on Nasdaq tomorro

      9/6/23 6:00:00 AM ET
      $APGE
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiondVax Reports Second Quarter Financial Results and Provides Business Update

      JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update. Second Quarter 2023 Financial Summary R&D expenses for the three months ended June 30, 2023, amounted to $1.45 million compared with $1.97 million for the three months ended June 30, 2022.Marketing, general and administrative expenses for the three months ended June 30, 2

      8/11/23 9:00:00 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

      JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax's multi-faceted plan to regain compliance with Nasdaq's Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance. As previously disclosed, BiondVax received a deficiency letter dated May 1, 2023, from Nasdaq notifying the Company that it is not in compliance with the minimum stockholders' equity requirement for con

      8/1/23 4:01:00 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BVXV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Margolin Yael claimed ownership of 66,800 units of Ordinary Shares (Amendment)

      3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

      1/23/23 8:16:22 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3: New insider Laster Morris C claimed ownership of 66,800 units of Ordinary Shares (Amendment)

      3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

      1/23/23 8:10:29 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3: New insider Lowell George claimed ownership of 421,680 units of Ordinary Shares (Amendment)

      3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

      1/23/23 8:04:49 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BVXV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BVXV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $BVXV
    SEC Filings

    See more
    • SEC Form SC 13G filed by BiondVax Pharmaceuticals Ltd.

      SC 13G - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

      2/14/24 3:53:32 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by BiondVax Pharmaceuticals Ltd. (Amendment)

      SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

      1/24/24 2:33:59 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by BiondVax Pharmaceuticals Ltd. (Amendment)

      SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

      1/2/24 4:54:14 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aegis Capital initiated coverage on BiondVax Pharmaceuticals with a new price target

      Aegis Capital initiated coverage of BiondVax Pharmaceuticals with a rating of Buy and set a new price target of $7.00

      1/26/22 10:21:55 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by BiondVax Pharmaceuticals Ltd.

      EFFECT - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

      2/14/24 12:15:33 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form F-3 filed by BiondVax Pharmaceuticals Ltd.

      F-3 - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

      1/30/24 4:19:12 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by BiondVax Pharmaceuticals Ltd.

      6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

      1/18/24 11:50:50 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BVXV
    Leadership Updates

    Live Leadership Updates

    See more
    • BiondVax Announces Third Quarter 2020 Financial Results & Business Update

      JERUSALEM, Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced its third quarter financial results for the quarter ended September 30, 2020. Third Quarter 2020 Financial Summary Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.441 (NIS/$US) as at September 30, 2020. Total operating income for the third quarter was NIS 55.6 million (approximately $16.1 million) compared with a total operating loss of NI

      1/28/21 3:23:00 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiondVax Announces Appointment of Amir Reichman as New CEO

      JERUSALEM, Jan. 21, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on development and manufacturing of products for the prevention and treatment of infectious diseases, today announced the appointment of Amir Reichman as its new CEO. Mr. Reichman and Ron Babecoff, BiondVax's founder and current CEO, will share duties during a transition period while Mr. Reichman completes his work obligations at GlaxoSmithKline (GSK), a global pharmaceutical company. Effective March 2, 2021, Mr. Reichman will assume the CEO position full time and Mr. Babecoff will continue as Senior Advisor to the Company. Continue Reading BiondVa

      1/21/21 7:15:00 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care